Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

GC012F Remains Safe, Generates Durable Responses in Relapsed/Refractory Myeloma

June 4th 2023

The BCMA- and CD19-targeted CAR T-cell therapy GC012F continued to demonstrate a favorable safety profile with no new safety signals, and it elicited deep and durable responses in patients with relapsed/refractory multiple myeloma.

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

June 4th 2023

Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.

Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma

June 4th 2023

Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.

Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple Myeloma

June 3rd 2023

Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Linvoseltamab Shows High Response Rate, Manageable Toxicity for Pretreated Myeloma

June 3rd 2023

The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma.

PHE855 Generates High Response and MRD Negativity Rates in Relapsed/Refractory Myeloma

June 3rd 2023

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy in R/R Multiple Myeloma

June 3rd 2023

Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.

Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple Myeloma

June 2nd 2023

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Dr Zonder on Ongoing Research at Karmanos Cancer Institute in Multiple Myeloma

June 1st 2023

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

May 31st 2023

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Improving Durability of Responses Is a Key Next Step for CAR T-cell Therapy in Myeloma

May 26th 2023

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Dr Zonder on the Real-World Use of Ixazomib-based Therapy in R/R Multiple Myeloma

May 26th 2023

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Dr Bal on the Clinical Implications of Cilta-cel in R/R Multiple Myeloma

May 25th 2023

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

​​Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma

May 24th 2023

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Dr Kin on Clinical Implications of the FDA Approval of Teclistamab in R/R Multiple Myeloma

May 23rd 2023

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

Dr Tauro on Next Steps for the Investigation of Novel Autophagy Inhibitors in R/R Multiple Myeloma

May 22nd 2023

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Investigation of CAR T-cell Therapy in Earlier Treatment Lines Could Continue to Alter Treatment Sequencing in Myeloma

May 22nd 2023

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple Myeloma

May 19th 2023

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Dr Bal on Ide-cel in R/R Multiple Myeloma

May 18th 2023

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

NEXT PAGE
PREVIOUS PAGE
x